Skip to content
PulseMS
Log inJoin
Research & community

MS research, together.

MS research in plain English. Perspectives from people who understand.

Research evidence filters

Filters apply to reviewed research. Unknown dates and unassessed posts are excluded when a corresponding filter is active.

Reset filters
Topics & sourcesExplore
Research and community updates, newest first.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyNot reportedTrial registry

Study of Disability Mechanisms in Immune-Mediated CNS Disorders Including Humans

This study is designed to explore how disability develops in people with immune-mediated injuries to the central nervous system (CNS). It involves 2400 subjects, including both patients showing symptoms of CNS damage and healthy volunteers for comparison. Patients may also have follow-up tests with NIH researchers after 1-2 years.

What this does not proveThe study has not posted any results, and its planned enrollment and endpoints do not constitute findings.
#Neuroinflammation
View abstract on PubMedAI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyPhase 2Trial registry

Safety of Sequential Rituximab and Cladribine Treatment in Relapsing-Remitting MS Patients

The HiHat trial is underway to assess the safety of rituximab followed by cladribine in individuals with relapsing-remitting multiple sclerosis (RRMS). It aims to determine if the rate of serious adverse events (SAEs) is low following this sequential treatment.

What this does not proveResults are not yet available from this Phase 2 trial, and the planned enrollment and endpoints do not constitute findings.
#Other
View abstract on PubMedAI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyNot reportedTrial registry

Clinical Study on Pulmonary Lymphangioleiomyomatosis (LAM) in Humans

A study has been planned to enroll 2000 individuals with pulmonary lymphangioleiomyomatosis (LAM) to investigate the disease's clinical course and underlying cellular and molecular mechanisms using the Toshiba Aquilion One CT device.

What this does not proveNo results have been reported yet; the planned enrollment and endpoints currently do not provide any findings.
#MSResearch
View abstract on PubMedAI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyPhase 1Trial registry

Ferumoxytol in Brain MRI for Multiple Sclerosis and Healthy Volunteers

In a Phase 1 pilot study, ferumoxytol was evaluated as a safe contrast agent in brain MRI for healthy volunteers and individuals with multiple sclerosis. The safety was demonstrated by the absence of long-term signal changes, and it was found that ferumoxytol enhancement could be observed in MS lesions using a 7-tesla MRI. However, explicit results have not been reported yet.

What this does not proveThe study has no clear results published; it primarily aimed to assess safety and imaging techniques rather than confirm findings.
#Other
View abstract on PubMedAI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyObservationalTrial registry

Caregiver Observational Study on MS and Related Factors

An observational study is planned to explore the relationships between the severity of multiple sclerosis (MS) and various factors impacting caregivers, such as their sleep quality, physical activity, body awareness, perceived stress, and caregiver burden. The study aims to include 68 caregivers from Başkent University Hospital but has not yet begun recruitment, and no results have been reported.

What this does not proveSince the study has not yet recruited participants or reported any findings, no conclusions can be drawn regarding the associations investigated.
#MSResearch
View abstract on PubMedAI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyObservationalPeer-reviewed

Knowledge of Multiple Sclerosis Among Primary Care Physicians in Bahrain

In a survey of 211 primary care physicians in Bahrain, 58.3% recognized multiple sclerosis (MS) as an immune-mediated disorder affecting the central nervous system. The majority identified relapsing-remitting MS as the most common type (60.2%) and preferred MRI for diagnosis (75.8%). Females and younger physicians displayed better knowledge, while only about half knew the relapse criteria and treatment protocol.

What this does not proveThe study reflects knowledge at a single point in time and had a response rate of only 49.3%, which may limit the generalizability of the findings.
#MSResearch
View abstract on PubMedPMID 42844602AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyObservationalPeer review unconfirmed

Risk of Degenerative Spine Disease in Human Patients with Multiple Sclerosis

In a study of 288,401 matched patients, those with multiple sclerosis (MS) had a higher incidence of composite degenerative spine disease (DSD) at 12.7% compared to 9.3% in migraine patients without aura, resulting in a risk ratio of 1.36. Patients with MS underwent fewer spine surgeries (1.9% vs 2.4%) and interventional pain procedures (3.2% vs 5.1%).

What this does not proveThe study does not establish causation between MS and DSD due to its observational design, and reliance on a single database may limit the generalizability of the findings.
#MSResearch
View abstract on PubMedPMID 42844679AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyObservationalPeer-reviewed

Health Utilities and Costs for Multiple Sclerosis

A survey of 5,913 MS patients revealed a mean utility score of 0.576. The highest scores were for relapsing-remitting MS at 0.667, while secondary progressive MS had the lowest at 0.385. Total MS-related costs over three months averaged £2807, with costs ranging widely based on disability status (EDSS).

What this does not proveThe study does not establish causal relationships and does not fully explore variability related to age, sex, MS types, and EDSS scores beyond reported data.
#MSResearch
View abstract on PubMedPMID 42843719AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedSubjects not reportedNot reportedPeer review unconfirmed

Potential Role of ER-Nε-lysine Acetylation in Neurological Disorders

An article discusses the role of ER-Nε-lysine acetylation in maintaining protein stability in the context of neurological disorders, with a particular mention of its potential relevance to multiple sclerosis, but does not provide specific evidence or findings related to MS.

What this does not proveThe study lacks concrete evidence or results about multiple sclerosis; its relevance to the disease remains unproven.
#MSResearch
View abstract on PubMedPMID 42843274AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedSubjects not reportedNot reportedPeer review unconfirmed

HLA-DRB1*15:01 and Intermediate Uveitis in Children

In a study of 65 patients with non-infectious uveitis, those with the HLA-DRB1*15:01 genotype experienced intermediate uveitis nearly three times more than those without it (70% vs. 24%). They also had less anterior chamber cells, more vitreous floaters, and greater capillary leakage features, suggesting distinct clinical differences based on this genetic marker.

What this does not proveThe exact role of HLA-DRB1*15:01 typing in predicting the risk of multiple sclerosis is still unknown.
#MSResearch
View abstract on PubMedPMID 42842354AI summary of a published abstract. Not medical advice.